The world has never seen a global vaccine rollout on the scale of the COVID-19 response. Ten to fourteen billion doses of vaccine are estimated to be required to protect the global population against death and severe illness while controlling transmission. Vaccine manufacturers, regulatory authorities, logistics experts, healthcare systems, and healthcare practitioners are facing the challenge of producing and delivering these billions of doses while ensuring that every dose administered is safe and effective. High global demand and insufficient supply have resulted in the vastly inequitable global distribution of COVID-19 vaccines, and these factors also have created economic incentives for the deliberate falsification of vaccines.

USP and Fight the Fakes Alliance is convening a panel discussion focusing prevention, detection and response framework to substandard and falsified medicines, building on the recently launched USP White Paper providing strategies and tools to use in global settings while confronting the expected rise in substandard and falsified COVID-19 vaccines. With the participation of the relevant stakeholders, the meeting aims to discuss the strategies and interventions and gain insights on the problem from different regions around the world.

You are warmly invited to join this webinar taking place during Fight the Fakes Week (6-12 December), our annual global campaign raising awareness about the dangers of substandard and falsified medical products.



  • Mr. Adam Aspinall, Senior Director, Access and Product Management at Medicines for Malaria Venture; Chair, Fight the Fakes (FTF) Alliance
  • Ms. Sireesha Yadlapalli, Vice President, International Government and Regulatory Affairs, USP (moderator)

Panel Discussion

  • Dr. John B. Hertig, Vice-Chair and Associate Professor, Department of Pharmacy Practice, Butler University College of Pharmacy and Health Sciences
  • Ms. Oksana Pyzik, Global Engagement Lead & Lecturer in Global Health at the UCL School Pharmacy, Research Department of Practice & Policy
  • Ms. Pernette Bourdillon Esteve, Incidents and Substandard/Falsified Medical Products, Regulation and Safety, World Health Organization
  • Dr. Yvette Madrid, Vaccines Program Director, USP Global Health
  • Mr. Rafael Andres Diaz- Granados, Executive Director , Latin American Federation of the Pharmaceutical Industry (FIFARMA)

Closing Remarks

  • Ms. Sireesha Yadlapalli, Vice President, International Government and Regulatory Affairs, USP

Download the banners and spread the word!